| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 26, 2007 | Biotech financing: Will ImaRx break the IPO slump? | (UPDATED: See below.)
It’s been a long, barren summer for biotech IPOs, but ImaRx, the blood-clot company we featured here, finally managed to bull its way into the public markets. The company, which withdrew an earlier $75 million IPO and ... |
| Apr 23, 2007 | The boulevard of broken IPO dreams | Dollars may be sluicing into biotechnology via venture investments and acquisitions these days, but there’s still one place that private biotechs can’t seem to catch a break, and that’s in the public markets.
The latest casualty here is PTC... |
| Apr 6, 2007 | Is Big Pharma tiptoeing into embryonic stem cells? | (Note: This item has been copied over to the Life Sciences page from its original location on the VentureBeat main page. To view it in its original context, with comments, click here.)
For what appears to be the first time, a major drug com... |
| Apr 6, 2007 | Is Big Pharma tiptoeing into embryonic stem cells? | For what appears to be the first time, a major drug company has plunked down a significant equity investment in embryonic stem cells.
Earlier today, VentureWire reported (sub required) that Novocell, an early-stage San Diego biotech that ai... |
| Controversial autism study claims disorder may not be genetic (Morning Read) | Current medical news and unique business news for anyone who cares about the healthcare industry.
Controversial study: Autism may not be a genetic disorder. A controversial new analysis of autism in twins published in Archives of General Ps... |